EsophaCap for Detecting Esophageal and Gastric Cancers
This study is looking for better ways to find Barrett's Esophagus (a condition that can lead to cancer), esophageal cancer, and gastric (stomach) cancer early. Researchers are using a special capsule called EsophaCap to collect cells from your esophagus and stomach. They will then look for specific changes in your genes (biomarkers) that could help tell the difference between these conditions and healthy tissue. The goal is to find the best gene markers to identify these cancers and Barrett's Esophagus. You might be able to join if you are over 18, having an esophagogastroduodenoscopy (a procedure to look at your esophagus, stomach, and small intestine) at Johns Hopkins Hospital, and can swallow a capsule. The study is currently unclear on its recruitment status.
- Study design
- This is an observational study planning to include 2500 participants. It is not specified if it is randomized or blinded.
- What's involved
- You would need to be undergoing an esophagogastroduodenoscopy and be able to swallow a capsule. The gene marker differences are measured at 1 day.
- Compensation
- Not stated in the trial record.
- Follow-up
- Not specified.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
EsophaCap for the Detection of Early Esophageal Carcinoma
At a glance
Conditions
Where it's being run
2 sites across 1 statesStudy leadership
- Stephen Meltzer, M.D. · PRINCIPAL_INVESTIGATOR · Johns Hopkins University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Difference in methylation of gene markers to discriminate Barrett's esophagus from non-pathological esophageal squamous and gastric cardia tissue.1 day
Using DNA methylation, we plan on identifying, from a pool of highly selected marker candidates, the best biomarkers that are aberrantly methylated in Barrett's esophagus versus control in order to differentiate between subjects who have Barrett's esophagus and those who do not have Barrett's esophagus. This is measure using methylation index and the calculated probability score from different methylation index values.
- Difference in methylation of gene markers to discriminate esophageal carcinoma from non-pathological esophageal squamous and gastric cardia tissue.1 day
Using DNA methylation, we plan on identifying, from a pool of highly selected marker candidates, the best biomarkers that are aberrantly methylated in esophageal cancer versus control in order to differentiate between subjects who have esophageal cancer and those who do not. This is measure using methylation index and the calculated probability score from different methylation index values.
- Difference in methylation of gene markers to discriminate gastric cancer from non-pathological esophageal squamous and gastric cardia tissue.1 day
Using DNA methylation, we plan on identifying, from a pool of highly selected marker candidates, the best biomarkers that are aberrantly methylated in gastric cancer versus control in order to differentiate between subjects who have gastric cancer and those who do not. This is measure using methylation index and the calculated probability score from different methylation index values.